MedTrace Logo

A Phase 1 Study of CX1003 (Kanitinib) in Patients with Advanced Solid Tumors

NCT04093466 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 126

Last updated 2024-10-17

No results posted yet for this study

Summary

CX1003 is a novel multi-target tyrosine kinase inhibitor that is designed to primarily inhibit vascular endothelial growth factor receptor 2 (VEGFR2) and hepatocyte growth factor receptor (HGFR/MET). This study aimed to evaluate the safety, pharmacokinetics, and antitumor activity of CX1003 in patients with refractory advanced or metastatic solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

CX1003

Oral dose A 4-day single dose period, followed by a period of daily-dose in continuous 28-day treatment cycle (the 1st cycle) or 21-day treatment cycles (the 2nd cycle and beyond) Dosage range: 25 mg, 50mg, 75mg, 100mg,125mg,150mg,175mg

Sponsors & Collaborators

  • Chinese Academy of Medical Sciences

    collaborator OTHER

  • West China Hospital

    collaborator OTHER

  • Beijing Tongren Hospital

    collaborator OTHER

  • Beijing Konruns Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Yuankai Shi, Doctor · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-27
Primary Completion
2025-10-31
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04093466 on ClinicalTrials.gov